feed,title,long_url,short_url
Benzinga,argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session,https://www.benzinga.com/pressreleases/20/10/g17777315/argenx-presents-additional-efgartigimod-data-from-global-phase-3-adapt-trial-at-the-myasthenia-gra,https://j.mp/34nqxyx
